Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Chen Website

Jinqiu Chen, Ph.D.

Selected Publications

1)  Kedei N, Chen JQ, Herrmann MA, Telek A, Goldsmith PK, Petersen ME, Keck GE, Blumberg PM.
Molecular systems pharmacology: isoelectric focusing signature of protein kinase cd provides an integrated measure of its modulation in response to ligands.
J. Med. Chem. 57: 5356-69, 2014.
2)  Chen JQ, Heldman MR, Herrmann MA, Kedei N, Woo W, Blumberg PM, Goldsmith PK.
Absolute quantitation of endogenous proteins with precision and accuracy using a capillary Western system.
Anal. Biochem. 2013.
3)  Kedei N, Lewin NE, Géczy T, Selezneva J, Braun DC, Chen J, Herrmann MA, Heldman MR, Lim L, Mannan P, Garfield SH, Poudel YB, Cummins TJ, Rudra A, Blumberg PM, Keck GE.
Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.
ACS Chem. Biol. 8: 767-77, 2013.
4)  Chen JQ, Lee JH, Herrmann MA, Park KS, Heldman MR, Goldsmith PK, Wang Y, Giaccone G.
Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer.
Mol. Cancer Ther. 2013.
5)  Xin HW, Ambe CM, Hari DM, Wiegand GW, Miller TC, Chen JQ, Anderson AJ, Ray S, Mullinax JE, Koizumi T, Langan RC, Burka D, Herrmann MA, Goldsmith PK, Stojadinovic A, Rudloff U, Thorgeirsson SS, Avital I.
Label-retaining liver cancer cells are relatively resistant to sorafenib.
Gut. 2013.
6)  Bakhsheshian J, Hall MD, Robey RW, Herrmann MA, Chen JQ, Bates SE, Gottesman MM.
Overlapping Substrate and Inhibitor Specificity of Human and Murine ABCG2.
Drug Metab. Dispos. 2013.
7)  Kohn EA, Yang Y, Du Z, Nagano Y, Van Schyndle CM, Herrmann MA, Heldman M, Chen J, Stuelten CH, Flanders KC, Wakefield LM.
Biological responses to TGF-beta in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression.
Mol. Cancer Res. 10: 1389-99, 2012.
8)  Kedei N, Telek A, Czap A, Lubart ES, Czifra G, Yang D, Chen J, Morrison T, Goldsmith PK, Lim L, Mannan P, Garfield SH, Kraft MB, Li W, Keck GE, Blumberg PM.
The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line.
Biochem. Pharmacol. 81: 1296-308, 2011.
Click Here to View Collapsed Bibliography.

This page was last updated on 7/28/2014.